Your browser doesn't support javascript.
loading
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial
Mimura, Maria Angela Martins; Hirota, Silvio Kenji; Sugaya, Norberto Nobuo; Sanches Jr, José Antonio; Migliari, Dante Antonio.
Afiliação
  • Mimura, Maria Angela Martins; University of São Paulo. School of Dentistry. Department of Stomatology. São Paulo. BR
  • Hirota, Silvio Kenji; University of São Paulo. School of Dentistry. Department of Stomatology. São Paulo. BR
  • Sugaya, Norberto Nobuo; University of São Paulo. School of Dentistry. Department of Stomatology. São Paulo. BR
  • Sanches Jr, José Antonio; University of São Paulo. Faculdade de Medicina. Hospital das Clínicas. Division of Dermatology. São Paulo. BR
  • Migliari, Dante Antonio; University of São Paulo. School of Dentistry. Department of Stomatology. São Paulo. BR
Clinics ; Clinics;64(3): 193-198, 2009. tab
Article em En | LILACS | ID: lil-509423
Biblioteca responsável: BR1.1
ABSTRACT

PURPOSE:

This study aimed to evaluate the efficacy of the systemic drugs thalidomide, dapsone, colchicine, and pentoxifylline in the treatment of severe manifestations of RAS.

METHODS:

An open, 4-year clinical trial was carried out for 21 consecutive patients with severe RAS. Initially, patients were given a 2-week course of prednisone to bring them to a baseline status. Simultaneously, one of the four test drugs was assigned to each patient to be taken for a period of 6 months. During the course of the trial, patients were switched to one of the other three drugs whenever side effects or a lack of satisfactory results occurred, and the 6-month limit of the treatment was then reset.

RESULTS:

The most efficient and best-tolerated drug was thalidomide, which was administered to a total of eight patients and resulted in complete remission in seven (87.5 percent). Dapsone was prescribed for a total of nine patients, of whom eight (89 percent) showed improvement in their symptoms, while five showed complete remission. Colchicine was administered to a total of ten patients, with benefits observed in nine (90 percent), of whom four showed complete remission. Pentoxyfilline was administered to a total of five patients, with benefits observed in three (60 percent), of whom one patient showed complete remission.

CONCLUSION:

The therapeutic methods used in this trial provided significant symptom relief. Patients experienced relapses of the lesions; however, this occurred after withdrawal of their medication during the follow-up period.
Assuntos
Palavras-chave
Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Pentoxifilina / Estomatite Aftosa / Talidomida / Colchicina / Dapsona Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Child / Female / Humans / Male Idioma: En Revista: Clinics Assunto da revista: MEDICINA Ano de publicação: 2009 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil
Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Assunto principal: Pentoxifilina / Estomatite Aftosa / Talidomida / Colchicina / Dapsona Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adolescent / Adult / Aged / Child / Female / Humans / Male Idioma: En Revista: Clinics Assunto da revista: MEDICINA Ano de publicação: 2009 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil